NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it has signed a definitive agreement to acquire Crescendo Bioscience for $270 million in cash, though the amount Myriad will pay will be reduced by $25 million for repayment of a loan it previously made to Crescendo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.